Patents by Inventor Herve Bouchard

Herve Bouchard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors
    Publication number: 20080004300
    Abstract: The invention relates to compounds of formula (I): in which R1, R2, L1, X, R3, A, R4, R4?, R4?, R4??, R5, Y and L2 are as herein defined, salts and prodrugs thereof, to their use as protein kinase inhibitors, and to methods of treating diseases comprising adminstration thereof.
    Type: Application
    Filed: January 26, 2007
    Publication date: January 3, 2008
    Applicant: Aventis Pharma S.A.
    Inventors: Hartmut Strobel, Sven Ruf, Dominique Lesuisse, Conception Nemecek, Youssef El-Ahmad, Stefan Guessregen, Anne Lebrun, Kurt Ritter, Didier Benard, Augustin Hittinger, Herve Bouchard
  • Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
    Publication number: 20070232572
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds and their therapeutic application in humans.
    Type: Application
    Filed: February 6, 2004
    Publication date: October 4, 2007
    Applicants: Aventis Pharma S.A., Centre National De La Recherche Scientifique, Museum National D'Histoire Naturelle, Institut Curie, Commissariat A L'Energie Atomique, Universite De Reims Champagne-Ardenne
    Inventors: Augustin Hittinger, Thomas Caulfield, Patrick Mailliet, Herve Bouchard, Eliane Mandine, Jean-Louis Mergny, Lionel Guittat, Jean-Francois Riou, Dennis Gomez, Chafke Belmokhtar
  • Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof
    Publication number: 20070161626
    Abstract: Disclosed are novel substituted indazole compounds, pharmaceutical compositions comprising such compounds, and methods of treatment comprising such compounds.
    Type: Application
    Filed: December 4, 2006
    Publication date: July 12, 2007
    Applicant: Aventis Pharma S.A.
    Inventors: Frank Halley, Michel Tabart, Herve Bouchard, Catherine Souaille, Alain Le Brun, Fabrice Viviani, Laurence Gauzy-Lazo, Pascal Desmazeau, Odile Angouillant-Boniface, Bruno Filoche-Romme
  • AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM
    Publication number: 20060270649
    Abstract: Disclosed are azetidine derivatives of formula: their optical isomers, their salts, their preparation and medicaments containing them.
    Type: Application
    Filed: May 25, 2006
    Publication date: November 30, 2006
    Applicant: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Marc Capet, Serg Grisoni, Jean-Luc Malleron, Serge Mignani, Augustin Hittinger
  • Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
    Patent number: 7132414
    Abstract: The present invention relates to pharmaceutical compositions containing, as active ingredient, a compound of formula: in which R1 represents a radical —NHCOR4 or —N(R5)—Y—R6, Y is CO or SO2, R4 represents a radical -alk-SO2—R11, -alk-SO2—CH?CH—R11 or Het substituted with —SO2—R11 or a phenyl radical substituted with —SO2—R11 or -alk-SO2—R11, R5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, to the novel derivatives of formula (I) and to their preparation, as well s to their use in treating various disorders of the nervous system.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: November 7, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
  • Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use
    Patent number: 7109340
    Abstract: Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: September 19, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Fabienne Thompson, Patrick Mailliet, Teresa Damiano, Marie-Pierre Cherrier, Francois Clerc, Frank Halley, Hervé Bouchard, Laurence Gauzy-Lazo, Bernard Baudoin, Catherine Souaille, Fabrice Viviani, Michel Tabart
  • Chemical derivatives and their application as antitelomerase agent
    Publication number: 20060199840
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: September 8, 2005
    Publication date: September 7, 2006
    Applicant: Aventis Pharma S.A.
    Inventors: Herve Bouchard, Augustin Hittinger
  • SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE
    Publication number: 20060199837
    Abstract: Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology.
    Type: Application
    Filed: May 23, 2006
    Publication date: September 7, 2006
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Fabienne Thompson, Patrick Mailliet, Teresa Damiano, Marie-Pierre Cherrier, Francois Clerc, Frank Halley, Herve Bouchard, Laurence Gauzy-Lazo, Bernard Baudoin, Catherine Squaille, Fabrice Viviani, Michel Tabart
  • Taxoids, their preparation and pharmaceutical composition containing them
    Patent number: 7074821
    Abstract: New taxoids of general formula (I), their preparation and pharmaceutical compositions containing them. In general formula (I), Ar represents an aryl radical, R represents a hydrogen atom or an acetyl, alkoxyacetyl or alkyl radical, R1 represents a benzoyl radical or a radical of formula R2—O—CO— in which R2 represents an optionally substituted alkyl radical, an alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl or heterocyclyl radical. The new products of general formula (I) have a remarkable antitumor activity.
    Type: Grant
    Filed: December 8, 1993
    Date of Patent: July 11, 2006
    Assignee: Aventis Pharma, S.A.
    Inventors: Hervé Bouchard, Jean-Dominique Bourzat, Alain Commercon
  • Chemical derivatives and their application as antitelomerase agent
    Patent number: 6995175
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: February 7, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Hervé Bouchard, Augustin Hittinger
  • Benzimidazoles
    Publication number: 20060014756
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Application
    Filed: January 4, 2005
    Publication date: January 19, 2006
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Michael Edwards, Paul Cox, Shelley Amendola, Stephanie Deprets, Timothy Gillespy, Christopher Edlin, Andrew Morley, Charles Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir Majid, John Reader, Lloyd Payne, Nawaz Khan, Michael Cherry
  • Azaindoles
    Publication number: 20050267304
    Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Application
    Filed: November 23, 2004
    Publication date: December 1, 2005
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Paul Cox, Tahir Majid, Justine Lai, Andrew Morley, Shelley Amendola, Stephanie Deprets, Christopher Edlin, Charles Gardner, Dorothea Kominos, Brian Pedgrift, Frank Halley, Timothy Gillespy, Michael Edwards, Francois Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel Bezard, Chantal Carrez
  • Pharmacological uses of azetidine derivatives
    Publication number: 20050130953
    Abstract: A method of treating or preventing Alzheimer's disease, Parkinson's Disease and/or schizophrenia, this method comprising administering to a patient in need of such treatment a compound of formula: in which R, R3 and R4 are as defined in the specification.
    Type: Application
    Filed: November 12, 2004
    Publication date: June 16, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael Myers
  • Azaindoles
    Patent number: 6897207
    Abstract: The invention is directed to physiologically active compounds of general formula (I): and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: May 24, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N. A. Bezard, Chantal Carrez
  • Benzimidazoles
    Patent number: 6897208
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: May 24, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael L. Edwards, Paul J. Cox, Shelley Amendola, Stephanie D. Deprets, Timothy A. Gillespy, Christopher D. Edlin, Andrew D. Morley, Charles J. Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir N. Majid, John C. Reader, Lloyd J. Payne, Nawaz M. Khan, Michael Cherry
  • Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use
    Publication number: 20050096345
    Abstract: Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology.
    Type: Application
    Filed: July 9, 2004
    Publication date: May 5, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Fabienne Thompson, Patrick Mailliet, Teresa Damiano, Marie-Pierre Cherrier, Francois Clerc, Frank Halley, Herve Bouchard, Laurence Gauzy-Lazo, Bernard Baudoin, Catherine Souaille, Fabrice Viviani, Michel Tabart
  • Pharmacological uses of azetidine derivatives
    Patent number: 6872717
    Abstract: A method of treating or preventing obesity, this method comprising administering to a patient in need of such treatment an effective amount of a compound of formula in which R, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: March 29, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
  • Acetindine derivatives, their preparation and medicaments containing them
    Patent number: 6858603
    Abstract: Disclosed are azetidine derivatives of formula: their optical isomers, their salts, their preparation and medicaments containing them.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: February 22, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Marc Capet, Serg Grisoni, Jean-Luc Malleron, Serge Mignani, Augustin Hittinger
  • Benzimidazole derivatives and their use as KDR kinase protein inhibitors
    Publication number: 20050009894
    Abstract: The invention discloses and claims benzimidazole compounds of formula (I): wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or a diastereoisomer of said compound of formula (I) or a pharmaceutically acceptable salt thereof; the use of compounds of formula (I) for the treatment of a disorder of proliferation of blood vessels, uncontrolled angiogenesis, a fibrotic disorder, a disorder of proliferation of mesangial cells, a metabolic disorder, allergy, asthma, thrombosis, a disease of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, solid tumors and cancers, pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents and pharmaceutical compositions comprising a compou
    Type: Application
    Filed: April 20, 2004
    Publication date: January 13, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Didier Babin, Alain Le Brun, Laurence Gauzy-Lazo, Herve Bouchard
  • Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
    Publication number: 20040248884
    Abstract: The present invention relates to a cyclic urea compound of formula I: 1
    Type: Application
    Filed: February 2, 2004
    Publication date: December 9, 2004
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Marcel Patek, Anil Nair, Augustin Hittinger, Conception Nemecek, Daniel Bond, Greg Harlow, Herve Bouchard, Jacques Mauger, Jean-Luc Malleron, Mark Palermo, Fahad Al-Obeidi, Thomas Faitg, Hartmut Strobel, Sven Ruf, Kurt Ritter, Youssef El-Ahmad, Dominique Lesuisse